Brent joined Canaan in 1999 as a member of Kauffman Fellows Program. Since joining the firm, he has led a number of successful investments in leading life sciences companies such as DexCom (DXCM – IPO), Revivant (ZOLL – Acq.), Peninsula Pharmaceuticals (JNJ – Acq.), Cerexa (FRX – Acq.), Calixa (CBST – Acq.), Durata Therapeutics (DRTX – IPO), and Elevation Pharmaceuticals (DNPUF – Acq.).
Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. His technical expertise as a professional engineer with several patents to his credit is an asset to Canaan’s innovation-driven portfolio companies.
Brent currently serves on several boards including Abyrx, a developer and manufacturer of therapeutic devices for use during surgical procedures; Data Sciences International, a pioneer and the global leader in implantable wireless sensors for medical research; Durata Therapeutics, a biopharmaceutical company pursuing late-stage clinical development of novel antibiotic programs; Endogastric Solutions, the leading company offering medical devices for treatment of reflux disease; Minimally Invasive Devices, Inc. (MID), developer of a franchise of products that substantially improve visualization during laparoscopic surgery; and Relievant Medsystems, maker of minimally invasive devices to relieve chronic back pain.
Brent earned an MBA from the Tuck School of Business at Dartmouth College after graduating with BS and MS in Mechanical Engineering from the University of Dayton.
Calixa Therapeutics (Acq. by Cubist Pharmaceuticals)
Cerexa (Acq. by Forest Labs)
Elevation Pharmaceuticals (Acq. by Sonovion)
Peninsula Pharmaceuticals (Acq. by Johnson & Johnson)
Revivant (Acq. by ZOLL)